Skip to main content
OpenTrials
Completed

NCT Number: NCT03212625

The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction

Many investigators have studied for prevention and care of Hand-Foot Skin Reaction(HFSR), and urea cream is typical representative. Recent study was performed prevention effect of urea cream for Hand-Foot Skin Reaction(HFSR) on 871 Chinese. But the study did not designed as placebo-control group and it had big defect in double-blinded.

Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect of urea cream on Korean patient group.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Korea University Guro Hospital

Seoul, 08308, South Korea

About this study

Sorafenib is multiple tyrosine kinase inhibitor. It blocks path that such as Raf-1, Vascular Endothelial Growth Factor Receptor (VEGFR), Platelet-Drived Growth Factor Receptor-β (PDGFR-β), c-Jit, Flt-3. Sorafenib was known to increase life rate about processed hepatocellular carcinoma. So it is advised as standard treatment for liver cancer patient who has processed Barcelona Clinic Liver Cancer (BCLC) disease period C.

Sorafenib related side effect has reported such as fatigue, diarrhea, vomit, nausea, pruritus, depilation, Hand-Foot Skin Reaction(HFSR). Among the symptoms, Hand-Foot Skin Reaction(HFSR) is the most occurrence after using sorafenib and major reason of drug dose de-escalation, it function as decrease anti-cancer effect of sorafenib. It is known for the reason of Hand-Foot Skin Reaction(HFSR) occurrence is caused by tyrosine kinase inhibitive action, and its characteristic symptom is known as keratocyte necrosis, dermal edema, parakeratosis, hyperkeratosis. The level is categorized grade 1,2,3 according to the severity.

The result of meta-analysis of 24 clinical trials that contained 6000 patients, Hand-Foot Skin Reaction(HFSR) occured 39% of sorafenib used patients and 9% of total patients had grade 3 Hand-Foot Skin Reaction(HFSR). But prevalence rate on hepatocellular carcinoma patients who used sorafenib is about 51% on Japanese, 45% on Asia-pacific patient (inclusive Korean) and 73.6% on Chinese. Prevalence rate of Hand-Foot Skin Reaction(HFSR) is different from result of each study, but about 50% of sorafenib used patients has had Hand-Foot Skin Reaction(HFSR) generally and Asian has more higher degree of prevalence rate. Therefore, prevent and care of Hand-Foot Skin Reaction(HFSR) on Korean hepatocellular carcinoma patients who used sorafenib is required.

Urea cream is typical representative for prevention and care of Hand-Foot Skin Reaction(HFSR). As stability-guaranteed drug, it is relatively cheap, locally affect and has used for psoriasis treatment. Also it is known for curative effacement on Hand-Foot Skin Reaction(HFSR) after use tyrosine kinase inhibitor such as sorafenib, sunitinib.

Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect of urea cream on Korean patient group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who was diagnosed with hepatocellular carcinoma, and was accompanied by impossible for radical treatment in disease period or do not reaction for local treatment, and the first time for sorafenib injection.
  • Standard of hepatocellular carcinoma diagnosis (2014, The Korean Liver Cancer Association)
  • Suitable on hepatocellular carcinoma pathologically
  • Hepatic nodule size over 1 cm on high-risk patients(hepatitis B virus positive, hepatitis C virus positive and liver cirrhosis) that identified by ultrasonography : In the case of suitable on hepatocellular carcinoma on over in one or two more dynamic contrast enhanced CT, dynamic contrast enhanced MRI, or MRI with Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid(Gd-EOB-DTPA)
  • Hepatic nodule size under 1 cm on high-risk patients that identified by ultrasonography : serum Alpha-fetoprotein(AFP) elevated over normal range constantly when hepatitis activity was restrained, and the case of suitable on hepatocellular carcinoma on over in two more the above image diagnoses

Exclusion criteria

  • Unsuitable on inclusion criteria
  • Patient who has had systemic anticancer therapy before (including sorafenib)
  • Patient who is receiving another treatment to hepatocellular carcinoma recent 3 weeks (allow to local treatment of metastasis lesion only)
  • Pregnant or Breastfeeding
  • Urea cream contraindication patient (Acute eczema, Inflammatory dermatopathy and Hypersensitivity on Urea and Methylparaben)

Treatment and study plan

Urea Cream 20%

Drug

Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)

Other names: Urea group

Placebos

Drug

Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)

Other names: Placebo group

Primary outcomes

  1. Cumulative incidence of Hand-Foot Skin Reaction(HFSR) on each group

    Time frame: 12 weeks treatment

    Comparison of cumulative incidence of HFSR between placebo group and urea cream group

Secondary outcomes

  1. Cumulative incidence of severe HFSR on each group

    Time frame: 12 weeks treatment

    Comparison of cumulative incidence of severe HFSR (grade 2 or grade 3) between placebo group and urea cream group

  2. Incidence of dose reduction or discontinuation of sorafenib due to HFSR on each group

    Time frame: 12 weeks treatment

    Comparison of incidence of dose reduction or discontinuation of sorafenib due to HFSR on each group

  3. Assessment of Quality Of Life (QOL)

    Time frame: 12 weeks treatment

    Assessment of QOL related to HFSR using The Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL) scoring system. HF-QOL instrument comprises a 20-item symptom scale and an 18-item daily activity scale. Each item was scored from 0 (not at all) to 4 (always or extremely). Therefore, the range of score for HF-QoL was from 0 to 152 points. (Ref. Anderson et al. The Oncoligist 2015;20:831-838)

  4. Overall survival

    Time frame: 12 weeks treatment

    Overall survival of patients

  5. Tumor response

    Time frame: 12 weeks treatment

    Tumor response using mRECIST criteria

  6. Other side effect

    Time frame: 12 weeks treatment

    The occurrence rate of other side effect excluding HFSR

  7. Incidence of HFSR on 2, 4, 8, and 12 weeks on each group

    Time frame: 2, 4, 8, and 12 weeks

    Comparison of incidence of HFSR on 2, 4, 8, and 12 weeks between placebo group and urea cream group

Sponsors and collaborators

Lead sponsor

Korea University Guro Hospital

Other

Collaborators

  • Hanmi Pharmaceutical Company Limited

Registry information

Official study title

The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Jul 11, 2017
Registry last updated
Aug 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.